Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
29.91
+0.35 (1.18%)
At close: Dec 5, 2025, 4:00 PM EST
29.92
0.00 (0.02%)
After-hours: Dec 5, 2025, 5:01 PM EST
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $15.00M in the twelve months ending September 30, 2025, up 118.88% year-over-year.
Revenue (ttm)
$15.00M
Revenue Growth
+118.88%
P/S Ratio
265.73
Revenue / Employee
$194,805
Employees
77
Market Cap
4.37B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CNTA News
- 6 days ago - What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company - The Motley Fool
- 19 days ago - Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying - The Motley Fool
- 23 days ago - Why Centessa Pharmaceuticals Stock Crushed the Market Today - The Motley Fool
- 24 days ago - Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 24 days ago - Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 4 weeks ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire